<DOC>
	<DOCNO>NCT00200525</DOCNO>
	<brief_summary>Study measure continue effectiveness apomorphine previous exposure least three month duration .</brief_summary>
	<brief_title>Continued Efficacy Safety Apomorphine Patients With Late-Stage Parkinsons Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Adults age â‰¥ 18 Men nonpregnant , nonlactating woman Women childbearing potential negative serum ( Beta HCG ) prestudy pregnancy test prior randomization Women childbearing potential use acceptable form contraception Patients clinical diagnosis idiopathic Parkinson 's Disease , i.e. , induce drug cause disease ; Patients classify stage ( IIIV ) Hoehn Yahr scale stag severity Parkinson 's Disease The patient must optimally maximize oral therapy regimen . Optimized oral antiparkinson medication must include levodopa/carbidopa inhibitor , either immediate delayed release form , plus least one direct act oral dopamine agonist least 30 day prior randomization Patients must receive apomorphine subcutaneous injection rescue therapy Off event least three month The minimum apomorphine baselinedosing requirement average least 2 dos per day week prior enrollment . Patients participate protocol APO401 , openlabel study primarily design collect safety data , eligible participation trial without termination participation APO401 Patients medical therapy clinically significant psychosis dementia relate ingestion antiparkinson medication . ( Patients hallucination central adverse reaction associate solely antiparkinson medication exclude . ) Patients history drug alcohol dependency within one year prior study enrollment Patients unstable clinically significant disease cardiovascular ( include orthostatic hypotension ) , hematologic ( include Coombs ' positive hemolytic anemia ) , hepatic , renal , metabolic , respiratory , gastrointestinal endocrinological system neoplasm within three month start study . Patinets history true allergy morphine derivative ( include apomorphine ) , sulfur , sulfur contain medication , sulfites , sulfate , Tigan ( R ) ( trimethobenzamide ) . Patients treat experimental agent ( apomorphine intermittent subcutaneous injection ) within 30 day study entry . Patients participation MYLANsponsored study APO202 exclude participation study . Patients whose apomorphine regimen characterize administration method intermittent subcutaneous injection . Patients could would sign Informed Consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>